List view / Grid view
16 April 2014 | By Janssen
Additional analyses presented in European and hepatitis C genotype 4 patient subgroups underscore benefit of simeprevir-based treatment regimens...
19 March 2014 | By Janssen
Additional Phase 3 data from the QUEST-1, QUEST-2 and PROMISE studies explore potential of simeprevir in genotype 1 hepatitis C patients while new ATTAIN data demonstrate a superior safety profile for simeprevir...
22 January 2014 | By Johnson & Johnson
Janssen global public health to oversee R&D and access strategy development for growing portfolio of transformational medicines...
9 December 2013 | By Johnson & Johnson
Sub-Saharan African Ministries of Health invited to submit expression of interest to participate in new effort donation program to be part of broader initiative to raise awareness and action...
22 November 2013 | By Johnson & Johnson
OLYSIO™ works by blocking the viral protease enzyme that enables the hepatitis C virus (HCV) to replicate in host cells...
19 April 2013 | By Johnson & Johnson
Janssen will receive $11.25 per ADS which will result in an after-tax gain of approximately $213m...
2 September 2011 | By Janssen Inc.
New biologic treatment option approved for chronic inflammatory bowel disease...
